FIGURE

Fig. 3

ID

ZDB-FIG-240729-121

Publication

Adekiya et al., 2024 - PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer

Other Figures

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

All Figure Page

Back to All Figure Page

Fig. 3

In vitro percent cell viability of LNCaP and PC-3 cells treated with docetaxel- and brusatol-loaded PSMA-targeted nanoparticles and controls at different concentrations (a) LNCaP cells (24 hours), (b) PC-3 cells (24 hours), (c) LNCaP cells (72 hours), (d) PC-3 cells (72 hours). Data are mean ± SD (n=4).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Biomed. Pharmacother.